Jenburkt Pharmaceuticals (524731) Q3 24/25 earnings summary

Executive summary

• Standalone unaudited financial results for the quarter and nine months ended 31st December 2024 were approved and reviewed by the Board and Audit Committee.

• Limited review by auditors found no material misstatements or non-compliance with SEBI regulations.

Financial highlights

• Revenue from operations for Q3 FY25 was ₹3,689.30 lakhs, up from ₹3,565.98 lakhs in Q3 FY24.

• Profit before tax for Q3 FY25 stood at ₹951.33 lakhs, compared to ₹784.04 lakhs in Q3 FY24.

• Net profit after tax for Q3 FY25 was ₹650.75 lakhs, up from ₹540.44 lakhs in Q3 FY24.

• Total comprehensive income for Q3 FY25 reached ₹593.16 lakhs, compared to ₹646.75 lakhs in Q3 FY24.

• Earnings per share (EPS) for Q3 FY25 was ₹14.75, up from ₹12.25 in Q3 FY24.

Outlook and guidance

• The company continues to operate exclusively in the pharmaceuticals segment, with no segment-wise reporting applicable.